TN2009000451A1 - Intrvenous and oral dosing of a direct-acting and reversible p2y12 inhibitor - Google Patents

Intrvenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Info

Publication number
TN2009000451A1
TN2009000451A1 TNP2009000451A TN2009000451A TN2009000451A1 TN 2009000451 A1 TN2009000451 A1 TN 2009000451A1 TN P2009000451 A TNP2009000451 A TN P2009000451A TN 2009000451 A TN2009000451 A TN 2009000451A TN 2009000451 A1 TN2009000451 A1 TN 2009000451A1
Authority
TN
Tunisia
Prior art keywords
reversible
intrvenous
inhibitor
acting
direct
Prior art date
Application number
TNP2009000451A
Other languages
English (en)
French (fr)
Inventor
Robert M Scarborough
Daniel D Gretler
Pamela B Conley
Patrick Andre
Athiwat Hutchaleelaha
David R Phillips
Anjali Pandey
Huang Wolin
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of TN2009000451A1 publication Critical patent/TN2009000451A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
TNP2009000451A 2007-05-02 2009-10-30 Intrvenous and oral dosing of a direct-acting and reversible p2y12 inhibitor TN2009000451A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91564907P 2007-05-02 2007-05-02
US94792107P 2007-07-03 2007-07-03
PCT/US2008/062518 WO2008137753A2 (en) 2007-05-02 2008-05-02 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Publications (1)

Publication Number Publication Date
TN2009000451A1 true TN2009000451A1 (en) 2011-03-31

Family

ID=39587015

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000451A TN2009000451A1 (en) 2007-05-02 2009-10-30 Intrvenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Country Status (17)

Country Link
US (2) US20090048216A1 (cg-RX-API-DMAC7.html)
EP (1) EP2079464A2 (cg-RX-API-DMAC7.html)
JP (1) JP2010526101A (cg-RX-API-DMAC7.html)
KR (1) KR20100029746A (cg-RX-API-DMAC7.html)
CN (1) CN101795682A (cg-RX-API-DMAC7.html)
AU (1) AU2008247483A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0811476A2 (cg-RX-API-DMAC7.html)
CA (1) CA2686203A1 (cg-RX-API-DMAC7.html)
CO (1) CO6241104A2 (cg-RX-API-DMAC7.html)
EA (1) EA200901473A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP099778A (cg-RX-API-DMAC7.html)
GT (1) GT200900284A (cg-RX-API-DMAC7.html)
IL (1) IL201834A0 (cg-RX-API-DMAC7.html)
MA (1) MA31663B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009011843A (cg-RX-API-DMAC7.html)
TN (1) TN2009000451A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008137753A2 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017402B1 (ru) * 2005-11-03 2012-12-28 Портола Фармасьютикалз, Инк. [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины, их формы, способы получения соединений, фармацевтические композиции, содержащие эти соединения, и их применение
BRPI0808422A2 (pt) * 2007-03-06 2015-06-23 Novartis Ag Compostos orgânicos bicíclicos adequados para o tratamento de condições inflamatórias ou alérgicas
CN101720324A (zh) * 2007-05-02 2010-06-02 波托拉医药品公司 [4-(6-氟-7-甲基氨基-2,4-二氧代-1,4-二氢-2h-喹唑啉-3-基)-苯基]-5-氯-噻吩-2-基-磺酰基脲盐、其相关的形式和方法
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
CN106075455A (zh) * 2008-12-30 2016-11-09 丹麦国家医院 鉴定发展成器官功能衰竭的风险提高的危重患者的方法及用于其治疗的化合物
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
DK2498731T3 (da) 2009-11-11 2020-03-02 Chiesi Farm Spa Fremgangsmåder til behandling eller forebyggelse af stenttrombose
CA2785487C (en) * 2009-12-23 2017-11-28 Ratiopharm Gmbh Solid pharmaceutical dosage form of ticagrelor
US20130165459A1 (en) 2010-01-12 2013-06-27 Norvartis Pharma Ag Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
WO2012072743A1 (en) * 2010-12-01 2012-06-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and kits for determining platelet susceptibility to activation in a patient
US8987285B2 (en) * 2010-12-03 2015-03-24 Portola Pharmaceuticals, Inc. Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof
MX393334B (es) 2017-03-15 2025-03-24 Idorsia Pharmaceuticals Ltd Administración subcutánea de un antagonista del receptor p2y12.
MA49452A (fr) 2017-06-23 2021-05-05 Chiesi Farm Spa Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire
CN107462648B (zh) * 2017-08-21 2019-09-27 盐城锦明药业有限公司 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
EA017402B1 (ru) 2005-11-03 2012-12-28 Портола Фармасьютикалз, Инк. [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины, их формы, способы получения соединений, фармацевтические композиции, содержащие эти соединения, и их применение

Also Published As

Publication number Publication date
EP2079464A2 (en) 2009-07-22
IL201834A0 (en) 2010-06-16
KR20100029746A (ko) 2010-03-17
GT200900284A (es) 2012-01-31
CA2686203A1 (en) 2008-11-13
ECSP099778A (es) 2010-01-29
EA200901473A1 (ru) 2010-06-30
CO6241104A2 (es) 2011-01-20
BRPI0811476A2 (pt) 2014-11-04
US20090048216A1 (en) 2009-02-19
CN101795682A (zh) 2010-08-04
JP2010526101A (ja) 2010-07-29
WO2008137753A2 (en) 2008-11-13
AU2008247483A1 (en) 2008-11-13
MX2009011843A (es) 2010-04-22
WO2008137753A3 (en) 2009-02-12
MA31663B1 (fr) 2010-09-01
US20120009172A1 (en) 2012-01-12

Similar Documents

Publication Publication Date Title
TN2009000451A1 (en) Intrvenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
CY2023002I1 (el) Συνθεσεις και χρησεις για αντιμετωπιση πολλαπλης σκληρυνσης
IL211825A (en) Compounds based on pyridine and pyrimidine for use as wnt signal transducer inhibitors, pharmaceutical formulations containing such compounds and used as drugs for the treatment and / or cancer prevention
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
ECSP099376A (es) Inhibidores de la actividad de la akt
HN2009003002A (es) Compuestos de piridopirimidinonas inhibidores de pi3k-alfa
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
PL1986669T3 (pl) Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia
MX341212B (es) Inhibidor de bromodominio de benzodiazepina.
TR201907804T4 (tr) Apaf-1 inhibitör bileşikleri.
BRPI0917444A2 (pt) composições farmacêuticas de retenção gástrica para o tratamento e prevenção de doenas do snc
TN2009000446A1 (en) P70 s6 kinase inhibitors
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
CL2008003798A1 (es) Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
MX2009011578A (es) 6-fenilpirimidinonas como moduladores de pim.
PL2222294T3 (pl) Kompozycje zawierające pochodne polifenoli stylbenowych oraz ich zastosowanie do zwalczania patologii i starzenia się organizmów żywych
MA32776B1 (fr) Inhibiteurs de l'akt et de la p70 s6 kinase
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
EP2137175A4 (en) NOVEL PHENANTHRENNEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF METABOLIC SYNDROME INVOLVING DISEASES
IN2012DN03428A (cg-RX-API-DMAC7.html)
MX2010005714A (es) Compuestos de piridina.
SG158091A1 (en) Imidazoazepinone compounds